InterCure (NASDAQ:INCR) vs. ImmuCell (NASDAQ:ICCC) Head to Head Comparison

ImmuCell (NASDAQ:ICCC) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, risk, earnings, valuation, institutional ownership and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for ImmuCell and InterCure, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1	0	0	0	1.00
InterCure	1	0	0	0	1.00

Profitability

This table compares ImmuCell and InterCure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
InterCure	N/A	N/A	N/A

Insider and Institutional Ownership

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by insiders. Comparatively, 0.2% of InterCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

ImmuCell has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, InterCure has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Valuation & Earnings

This table compares ImmuCell and InterCure”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64 million	3.64	-$1.04 million	($0.06)	-185.50
InterCure	$78.47 million	0.69	-$10.37 million	$0.03	32.80

ImmuCell has higher earnings, but lower revenue than InterCure. ImmuCell is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Summary

InterCure beats ImmuCell on 7 of the 11 factors compared between the two stocks.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

About InterCure

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.